Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07222488 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
A Phase 1 study of Bladder Cancer and Urinary Bladder Neoplasms, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 5
- Study locations
NCT07222488: Recruiting Phase 1 study of Bladder Cancer and Urinary Bladder Neoplasms, sponsored by Merck Sharp & Dohme.
NCT07222488 is a Phase 1 study of Bladder Cancer and Urinary Bladder Neoplasms that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 45 participants, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07222488, a Phase 1 study of Bladder Cancer and Urinary Bladder Neoplasms, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 5
- Study locations
Study Summary
Researchers are looking for new ways to treat high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder and has not spread to the bladder muscle or outside of the bladder. In standard treatment for HR NMIBC, doctors first remove the tumor with a procedure called transurethral resection of the bladder tumor (TURBT). Researchers want to learn if using MK-3120, the study medicine, can treat HR NMIBC after TURBT. The goal of this study is to learn about the safety of MK-3120 and if people tolerate it.
Primary Outcome
Any of the following toxicities will be considered a DLT: Hematuria leading to clot or obstruction; Grade (Gr) 4 thrombocytopenia; Gr 3 thrombocytopenia associated with clinically significant bleeding; Febrile neutropenia for more than 1 hour; Other Gr ≥3 hematologic toxicity lasting \>7 days; Nonhematologic AE ≥Gr 3 (with exceptions); ≥Gr 2 pneumonitis/ interstitial lung disease; Any ≥Gr 3 nonhematologic laboratory value if clinically significant medical intervention is required, leads to hosp
Conditions Studied
Interventions
- BIOLOGICAL MK-3120
Study Locations (5)
Other
- Rabin Medical Center ( Site 0062) - Petah Tikva
- Ankara University Health Practice and Research Hospitals ( Site 0132) - Ankara
California
- Michael G Oefelein Clinical Trials ( Site 0005) - Bakersfield
South Carolina
- Carolina Urologic Research Center ( Site 0006) - Myrtle Beach
Quebec
- CHU de Quebec - Hopital de l'Enfant-Jesus ( Site 0011) - Québec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2025-12-09 |
| Est. Completion | 2029-02-28 |
| Phase | Phase 1 |
What NCT07222488 shows while recruiting
NCT07222488 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which MK-3120 is the first listed.
NCT07222488 lists 5 locations in 4 states (Other, California, South Carolina).
Frequently Asked Questions
What is clinical trial NCT07222488 about?
NCT07222488 is a clinical study titled "A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)". Researchers are looking for new ways to treat high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder and has not spread to the bladder muscle or outside of the bladder. In standard treatment for HR NMIBC, doctors first remove the t...
What is the current status of trial NCT07222488?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2025-12-09. Estimated completion is 2029-02-28.
What conditions does trial NCT07222488 study?
This clinical trial studies the following conditions: Bladder Cancer, Urinary Bladder Neoplasms.
What interventions are being tested in trial NCT07222488?
The interventions under investigation include: MK-3120 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07222488?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07222488 being conducted?
This trial has 5 study locations across California, South Carolina, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07222488's enrollment target sits among peer trials
45 124th of 175 higher than 50 of 175 other Bladder Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Sacituzumab Govitecan Plus EV in Metastatic UC
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI